Navigation Links
Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
Date:1/8/2009

MONTREAL, Jan. 8 /PRNewswire/ - Aegera Therapeutics Inc. announced today the dosing of the first patient in a randomized Phase 2 study of AEG35156, their targeted antisense therapeutic in mid-stage development for multiple oncology indications.

The study, entitled "A Phase 2, Multicenter, Open-Label, Randomized Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given In Combination With Carboplatin/Paclitaxel or the Combination of Carboplatin/Paclitaxel Alone In Patients With Advanced Non Small Cell Lung Cancer" is being conducted in the United States in collaboration with U.S. Oncology and additional sites will be opened in Canada. The Principal Investigator of this study is Dr. Robert M. Jotte, of the Rocky Mountain Cancer Center in Denver, Colorado.

The primary objective of this study is to compare the efficacy of the standard of care for this patient population to the standard of care in combination with AEG35156. Recruitment for this trial is expected to be completed prior to the end of 2009.

"Preliminary evidence of activity was observed in the Phase 1 portion of this study and encouraged us to amend the clinical protocol to provide for a control arm for the Phase 2 portion of the study" stated Dr. Jacques Jolivet, Senior Vice-President of Clinical Development of Aegera.

"Our clinical program around AEG35156 continues to accelerate and expand as we seek to move this therapeutic forward to more advanced stages of clinical development," added Aegera's President and Chief Executive Officer, Dr. Michael J. Berendt. "The initiation of this randomized Phase 2 study in lung cancer follows very shortly after our publication of positive clinical data from our Phase 1/2 study in AML at the recent ASH conference in San Francisco and represents the first of multiple new clinical trials for this innovative therapy that we hope to announce over the course of 2009."

About AEG35156

Ca
'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
2. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
3. Aegera Therapeutics welcomes two experienced executives to its board of directors
4. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
5. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
6. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
7. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
8. Horizon Therapeutics Announces Senior Management Appointments
9. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
10. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
11. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2009)..., NEW BRUNSWICK, N.J., July 3 /PRNewswire-FirstCa...announced that the initial offering period of its ...stock of Cougar Biotechnology, Inc. (Nasdaq: CGR...2009. The offer was conducted through a wholly ow... Merger Sub, Inc. , , The depositary for the te...
(Date:7/2/2009)... BC, July 2 /PRNewswire-FirstCall/ - avVaa World H...obal biotechnology company, manufacturer and distr...skin and health care products, announced the engag...ponse media buying. , Lorie Campbell-Farley, Pres... be associated with Koeppel Direct, a world-class ...
(Date:7/1/2009)...statistical analysis technique that identifies and...d artifacts from experimental data could lead to m...als and nanostructures likely to have future indus...e adjustment by regression (SPAR), the technique c...equired to make conclusions, and help distinguish ...
(Date:7/1/2009)..., July 1 Johnson & Johnson...r of the Department of Molecular Biology at the Ma...se discoveries have led to novel cancer therapies ...er of the 2009 Dr. Paul Janssen Award for Biomedic...owned scientists selected Dr. Ullrich, who on Sept...
Breaking Biology Technology:Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology 2Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology 3Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology 4avVaa World Health Care Products, Inc. Announces Engagement of Koeppel Direct for their DRTV-Direct Response Television Media Buying Campaign 2New statistical technique improves precision of nanotechnology data 2New statistical technique improves precision of nanotechnology data 3New statistical technique improves precision of nanotechnology data 4Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 2Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 3Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 4Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 5
... , , , , , , , A maj...ymerase,chain reaction (RT-PCR) is the choice of...plied Science,has developed and optimized a wide... Each of these products has,different enzymatic ...ecific experiment than the other. The information ...
... , , , , , , , Polym...s,thawing of the various reagents, setting up a ...ividual reaction tubes. ,The various handling s...es and experimental error , bear the risk of c..., are time-consuming. , , , Fa...
... , , , , , , , Tra...nt,reverse transcriptase (RT) expressed in E. co...ctivity,DNA-dependent DNA polymerase activity, ...tivity. , , , , , Due to ...,Reverse Transcriptase, the individual enzymatic ...
... , , , , , , , Th..., , , , FastStart Taq DNA Polymerase...erase for hot start PCR, was introduced,in 2000....Start Taq DNA Polymerase has proven to be: The mo... , , , , Even the most challen...
Other Biology Technology:Reduce Errors and Save Time When Setting Up PCRs 2Increase the Power and Sensitivity for Your cDNA,Synthesis with the New Transcriptor Reverse Transcriptase 2Increase the Power and Sensitivity for Your cDNA,Synthesis with the New Transcriptor Reverse Transcriptase 3Increase the Power and Sensitivity for Your cDNA,Synthesis with the New Transcriptor Reverse Transcriptase 4Challenge the Performance of Your Hot-Start PCRs,with FastStart Taq DNA Polymerase and,the Novel FastStart High Fidelity PCR System 2
(Date:7/1/2009)... in mice responsible for repairing DNA strands dam..., providing additional evidence that such stress c...e conclusion of a recent study* in DNA Repair by...s and Technology (NIST), Oregon Health and Science...ool of Medicine (NYUSM). , Although all cells ne...
(Date:7/1/2009)...ntists, need to measure organic contaminants in hu...ds and Technology (NIST) has recently made four ne...r purchase. Developed in collaboration with the Ce...e human milk and serum SRMs have certified levels ...sticides, commonly found in the U.S. population. S...
(Date:7/1/2009)...rlands: For the first time, researchers have been...ial success or failure of IVF treatment in blood. ..., Ireland, told the 25th annual conference of the ...ogy today (Wednesday 1 July) that her research wou... but not for others. , Previous work in this are...
(Date:6/30/2009)... and Denmark have shown that if elderly men were g...d an appreciable muscle mass increase. Dr. Geoff G...l School, UK) says: "This raises the question: Can... fragility be ameliorated by the therapeutic appli...hope that MGF can also help sufferers of diseases ...
Breaking Biology News(10 mins):Genetically engineered mice yield clues to 'knocking out' cancer 2NIST issues human milk and blood serum SRMs for contaminant measurements 2Will IVF work for a particular patient? The answer may be found in her blood 2Will IVF work for a particular patient? The answer may be found in her blood 3BIO key 28R 29 Awarded 242 Million Biometric Contract by Multi National Company 3523 1BIO key 28R 29 Awarded 242 Million Biometric Contract by Multi National Company 3523 2Canyon County Idaho Sheriffs Office to Purchase Stinger S 200s 3521 1Canyon County Idaho Sheriffs Office to Purchase Stinger S 200s 3521 2Microsurgery on the brain of the fruit fly leads to new insights into irreparable nerve injuries 5791 1Microsurgery on the brain of the fruit fly leads to new insights into irreparable nerve injuries 5791 2Possible new approach to purifying drinking water 5789 1Possible new approach to purifying drinking water 5789 2Possible new approach to purifying drinking water 5789 3
...mazonian rainforest might not have yielded pots of...pe of gold mine: some of the globe,s richest soil ...round. , That,s not all. Scientists have a method ... Amazonian dark earths -- and say it can pull subs...vels of carbon dioxide in the Earth,s atmosphere, ...
...Medicine studies of Hispanic farmworkers in North ...rkers had skin disease and that workers need more ...tions, as well as potentially deadly diseases such... disease in migrant farmworkers. In one of the Wak...nston Counties were examined by a dermatologist wi...
... researcher has finally determined that duck-bille... to do with what many scientists suspected -- the ... has led to theories that the crests functioned as...erwater feeding. Now, David Evans, a PhD student i...uga, has been able to use a reconstructed brain ca...
...ming from The American Naturalist, biologists from... swans for more than two decades to explore a long... of eggs laid by a female bird ?known as "clutch s.... , "Extensive debate in the literature…was first ...verage clutch size differ from the most productive...
Other Biology News:GPSDB, the free Gene and Protein Synonyms DataBase 2Skin disease common among Hispanic farmworkers in North Carolina, research shows 2
...er and Sorter) large particle flow cytometers from...ometry to applications that were not previously co...d sorting. Our instruments are based on the same ... designed to accommodate much larger objects, up t...
Mouse polyclonal antibody raised against a partial recombinant TSEN2. NCBI Entrez Gene ID = 80746
Mouse polyclonal antibody raised against a partial recombinant AGTRAP. NCBI Entrez Gene ID = 57085
Mouse monoclonal antibody raised against a partial recombinant RAB11B. NCBI Entrez Gene ID = RAB11B
Biology Products: